#United States #New York #Rosen Law Firm #Securities Investigation #Disc Medicine

Rosen Law Firm Encourages Disc Medicine Investors for Class Action

On September 21, 2026, the Rosen Law Firm, a well-respected global firm dedicated to safeguarding investor rights, announced an ongoing investigation into securities fraud claims involving Disc Medicine, Inc. (NASDAQ: IRON). This inquiry has arisen following serious allegations suggesting that the company may have provided misleading information regarding its financial health to the investing community.

Investors who bought securities from Disc Medicine may have their rights violated and could be entitled to financial compensation without incurring upfront legal fees, thanks to the firm’s contingency fee structure. Currently, the Rosen Law Firm is preparing a class action suit aimed at recovering losses suffered by investors.

Understanding the FDA's Complete Response Letter

On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Disc Medicine concerning its application for a new drug, bitopertin. The FDA declared that it could not approve the application due to unresolved uncertainties that required further evidence. This announcement caused a significant market reaction, with Disc Medicine's stock plummeting by 22% on the same day, drastically affecting shareholder value.

This dramatic downturn in stock price and the subsequent potential for investors to claim losses emphasizes the need for affected shareholders to consider their options regarding legal recourse. Attorney Phillip Kim of the Rosen Law Firm advises those impacted to step forward: “If you purchased securities in Disc Medicine, you have the right to seek justice and potentially recover your losses.”

Why Choose Rosen Law Firm?

The Rosen Law Firm is noted for its track record in successfully advocating for investors. It has achieved noteworthy settlements and has been ranked highly by ISS Securities Class Action Services for its extensive number of settlements. For example, in 2019, the firm secured over $438 million for aggrieved investors. Notably, Laurence Rosen, a founding partner, was named a Titan of Plaintiffs' Bar by Law360, illustrating the firm's substantial expertise and credibility in handling securities class actions.

The firm's reputation reflects its commitment to providing qualified legal counsel to investors who have suffered financial losses as a result of negligence or misleading corporate practices. The Rosen Law Firm highlights that many firms issuing similar notices often lack the necessary experience and resources to competently litigate these cases.

Next Steps for Investors

Investors interested in participating in the class action case are encouraged to visit the Rosen Law Firm’s website at rosenlegal.com or to call them directly for more information about the proceedings. Immediate action is essential as there could be time constraints related to filing for the class action.

For inquiries, potential participants can also reach out via email at [email protected] or by contacting Phillip Kim directly at 866-767-3653. This outreach not only allows investors to gather critical information but also helps illuminate their path towards reclaiming financial losses related to the revelations surrounding Disc Medicine’s recent setbacks.

As the investigation proceeds, maintaining connection with updates through the firm's social media platforms will ensure that interested parties remain informed of developments and deadlines.

In conclusion, the situation surrounding Disc Medicine, Inc. serves as a reminder of the volatility in the healthcare and pharmaceutical sectors. Investors must remain vigilant and engaged to protect their financial interests.

Follow us for updates on LinkedIn, Twitter, and Facebook to stay informed about this and other important legal proceedings affecting investors today.